(Q47105068)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28873084%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

title

A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28873084%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28873084%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

author name string

J Cavenagh

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28873084%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

H Oakervee

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28873084%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

P Baetiong-Caguioa

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28873084%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

M Gharibo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28873084%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

N Rabin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28873084%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

M Kurman

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28873084%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

B Novak

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28873084%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

N Shiraishi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28873084%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

D Nakashima

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28873084%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

S Akinaga

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28873084%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

K Yong

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28873084%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

language of work or name

English

0 references

publication date

5 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28873084%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

29 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28873084%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

volume

117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28873084%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28873084%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

page(s)

1295-1302

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28873084%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International

29 March 2020

copyright license

start time

5 September 2017

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Cancer statistics, 2016

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5672925

Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5672925

The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5672925

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5672925

Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5672925

Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5672925

Inhibiting HSP90 to treat cancer: a strategy in evolution

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5672925

Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5672925

Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5672925

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5672925

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5672925

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5672925

Inhibitors of the HSP90 molecular chaperone: current status

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5672925

International uniform response criteria for multiple myeloma.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5672925

Antimyeloma activity of heat shock protein-90 inhibition.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5672925

Optimal two-stage designs for phase II clinical trials

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5672925

A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5672925

New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5672925

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5672925

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5672925

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5672925

Clinically relevant end points and new drug approvals for myeloma

15 August 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2017.302

7 January 2021

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2017.302

7 January 2021

A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2017.302

7 January 2021

Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2017.302

7 January 2021

Identifiers

DOI

10.1038/BJC.2017.302

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28873084%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28873084%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

PubMed publication ID

28873084

1 reference